News Author: Neil Osterweil Publish date: January 23, 2019
Helping patients understand the costs of chemotherapy did not lessen financial distress.
News Author: Neil Osterweil Publish date: January 22, 2019
Many patients with newly diagnosed cancers were unaware of their infection status, and some had no known risk factors.
News Author: Neil Osterweil Publish date: January 22, 2019
Risk for both myeloid and lymphoid neoplasms was higher among breast cancer survivors than in the general population.
News Author: Neil Osterweil Publish date: January 4, 2019
SAN DIEGO – A CAR T-cell construct engineered to enhance T-cell persistence and immune function induced high complete remission rates in a phase 1 ...
News Author: Neil Osterweil Publish date: January 4, 2019
SAN DIEGO – Follow-up of patients who survived at least 1 year after CAR T-cell infusions suggests that the technology is safe.
News Author: Neil Osterweil Publish date: January 2, 2019
SAN DIEGO – PFS was better post transplant with lenalidomide maintenance, but it’s too early to know whether OS will be improved.
News Author: Neil Osterweil Publish date: January 2, 2019
SAN DIEGO – QuANTUM-R is the first randomized trial to show a survival benefit over salvage chemotherapy in patients with FLT3-ITD mutated AML.
News Author: Neil Osterweil Publish date: December 28, 2018
SAN DIEGO—An interim analysis from the MAIA trial showed that adding daratumumab to lenalidomide and dexamethasone could significantly improve progres...
News Author: Neil Osterweil Publish date: December 27, 2018
Survivors of childhood Hodgkin lymphoma (HL) have a 14-fold higher risk of second cancers compared to the general population, according to new researc...
News Author: Neil Osterweil Publish date: December 21, 2018
SAN DIEGO – Patients with low diversity of intestinal microflora have worse overall survival after hematopoietic cell transplant.
News Author: Neil Osterweil Publish date: December 20, 2018
The findings highlight the need to screen high-risk subgroups of cancer survivors.
News Author: Neil Osterweil Publish date: December 19, 2018
The oral tyrosine kinase inhibitor was associated with durable responses and a high progression-free survival rate in patients with refractory or r...
News Author: Neil Osterweil Publish date: December 19, 2018
Disease-free and overall survival were significantly higher with modified FOLFIRINOX vs. gemcitabine, the current standard of care.
News Author: Neil Osterweil Publish date: December 19, 2018
Adding the PARP inhibitor to standard frontline chemotherapy offered a slight PFS benefit but no overall survival benefit.
News Author: Neil Osterweil Publish date: December 18, 2018
Studies of ovarian cancer tissues and cell lines suggest that bone morphogenetic protein-10 (BMP-10) may be a tumor suppressor.
